Page last updated: 2024-12-07

betamethasone acetate phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Betamethasone acetate phosphate is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive effects. It is commonly used in the treatment of a wide range of inflammatory and autoimmune conditions, such as asthma, eczema, arthritis, and inflammatory bowel disease. The compound is a derivative of betamethasone, and its acetate and phosphate esters enhance its potency and bioavailability. Betamethasone acetate phosphate is synthesized through a multi-step process involving chemical modifications of the steroid molecule. Its therapeutic efficacy is attributed to its ability to bind to glucocorticoid receptors within cells, leading to the regulation of gene expression and the suppression of inflammatory mediators. The compound is extensively studied for its potential in treating various inflammatory and autoimmune diseases, as well as for its anti-allergic and anti-pruritic effects. Research focuses on optimizing its delivery methods, investigating its long-term effects, and exploring its potential applications in other therapeutic areas.'

betamethasone acetate phosphate: RN given refers to parent mixt. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122053
MeSH IDM0069552

Synonyms (5)

Synonym
betamethasone acetate phosphate
celestone-r
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11beta,16beta)-, mixt. with (11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)pregna-1,4-diene-3,20-dione
52081-45-5
2,6-dimethylphenylboronicacid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"To study the pharmacokinetics of different betamethasone doses and preparations used to enhance fetal lung maturation in the maternal and fetal circulation of sheep and the adverse effects on fetal blood pressure."( Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses.
Coksaygan, T; Jusko, WJ; Nathanielsz, PW; Samtani, MN; Schwab, M, 2006
)
0.33
" Risk-benefit studies are needed to find the effective steroid dose with the least adverse effects."( Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses.
Coksaygan, T; Jusko, WJ; Nathanielsz, PW; Samtani, MN; Schwab, M, 2006
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" We therefore designed a study to capture the true pharmacokinetic profiles of betamethasone from these fast acting and dual-release formulations."( Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use.
Grant, A; Jusko, WJ; Lohle, M; Nathanielsz, PW; Samtani, MN, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection."( Disposition of betamethasone in parturient women after intramuscular administration.
Ashley, JJ; McBride, WG; Nation, RL; Petersen, MC, 1984
)
0.27

Dosage Studied

ExcerptRelevanceReference
"Antenatal corticotherapy is responsible for two different phases of fetal heart rate modifications that do not vary according to the corticosteroid or the dosage regimen."( Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone.
Devos, P; Leclerc, G; Puech, F; Subtil, D; Therby, D; Tiberghien, P; Vaast, P, 2003
)
0.32
" In light of this newly identified long terminal half-life for the betamethasone dual formulation, dosing practices for betamethasone in pregnancy need to be reassessed."( Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use.
Grant, A; Jusko, WJ; Lohle, M; Nathanielsz, PW; Samtani, MN, 2005
)
0.33
" Antenatal corticosteroid dosing regimens remain unoptimized and without maternal weight-adjusted dosing."( The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy.
Clarke, M; Eddershaw, PJ; Furfaro, L; Hanita, T; Ireland, D; Jobe, AH; Kemp, MW; Kumagai, Y; Molloy, TJ; Musk, GC; Newnham, JP; Payne, MS; Saito, M; Sato, S; Schmidt, A; Usuda, H; Watanabe, S, 2018
)
0.48
" These findings underscore the need to develop an optimized steroid dosing regimen that may improve both the efficacy and safety of antenatal corticosteroids therapy."( The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy.
Clarke, M; Eddershaw, PJ; Furfaro, L; Hanita, T; Ireland, D; Jobe, AH; Kemp, MW; Kumagai, Y; Molloy, TJ; Musk, GC; Newnham, JP; Payne, MS; Saito, M; Sato, S; Schmidt, A; Usuda, H; Watanabe, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (29.27)18.7374
1990's5 (12.20)18.2507
2000's17 (41.46)29.6817
2010's6 (14.63)24.3611
2020's1 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.41 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index74.87 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (27.91%)5.53%
Reviews0 (0.00%)6.00%
Case Studies6 (13.95%)4.05%
Observational0 (0.00%)0.25%
Other25 (58.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, Open-Label, Randomized Study to Compare the Pharmacokinetics and Pharmacodynamics of Single Dose Dexamethasone and Betamethasone Administered Orally and Intramuscularly in Healthy Female Subjects [NCT03668860]Phase 148 participants (Actual)Interventional2018-09-20Completed
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study [NCT03707795]Early Phase 16 participants (Actual)Interventional2017-08-21Completed
Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis. [NCT03054610]Phase 160 participants (Actual)Interventional2015-01-31Completed
[NCT00418353]0 participants Interventional2002-08-31Completed
Antenatal Corticoid Therapy for Fetal Lung Maturation in Late Preterm Pregnancies: a Randomized Controlled Trial [NCT00675246]320 participants (Anticipated)Interventional2008-05-31Completed
Randomized, Double Blind Comparison Trial of Prolotherapy (Dextrose) Compared to Corticosteroid Injection for the Treatment of Symptomatic Thumb Carpo-metacarpal Joint Arthritis [NCT00685880]2 participants (Actual)Interventional2008-05-31Terminated(stopped due to Unable to recruit adequate numbers of patients)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]